Astrazeneca Is Benefiting From Growing Business With New Drugs

Astrazeneca posted significant increases in cancer drugs in particular. Adjusted earnings per share fell by four percent to 94 cents, which is a little weaker than analysts expected. The company reaffirmed its goals for the full year. It continues to anticipate an increase in total sales in the high single-digit to low double-digit percentage range. The core earnings per share are expected to increase in the mid to high ten percent range. However, the further development of the Covid 19 pandemic could give rise to uncertainties for the outlook, admitted Astrazeneca. Alongside the duo Biontech and Pfizer and the US biotech group Moderna, Astrazeneca is one of the leading companies in the race for a vaccine against the coronavirus. The group confirmed that it would expect results from the crucial study with the vaccination later this year. In a US study, Astrazeneca now wants to test the Covid-19 vaccine on more subjects: 40,000 volunteers are now to take part in the study, and not just around 30,000.